TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06435975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will perform a baseline +4000 steps/day for the duration of the study. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants will complete a series of survey at multiple points throughout this study to assess quality of life issues. Questionnaires may be completed via paper forms with prepaid postage envelopes or using a REDCap online survey.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Lifestyle Coaching
Description: Participants will meet with a health coach, the Principal Investigator, to review baseline bowel habits and symptoms as well as discuss physical activity and potential strategies to achieve this goal, on a weekly basis for 12 weeks.
Study: NCT06479369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching training program
Description: The investigators will try to carry out a training based on motivational strategies for physical education teachers of the experimental group, with the aim of improving their motivational teaching style during physical education classes, and finally, to obtain benefits in their students, such as a greater adherence to physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching training program
Description: The investigators will try to carry out a training based on motivational strategies for physical education teachers of the experimental group, with the aim of improving their motivational teaching style during physical education classes, and finally, to obtain benefits in their students, such as a greater adherence to physical activity.
Study: NCT06345651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Individually MR-neuronavigated TMS, 600 pulses, 120% RMT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Individually MR-neuronavigated TMS, 600 pulses, 120% RMT
Study: NCT05769556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Gym Exercises
Description: Brain gym exercises is a collection of simple movements that function to stimulate the development of all parts of the brain synergistically.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: A Group of exercises
Study: NCT05945589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singapore A-Health Intervention
Description: The Singapore A-Health Intervention spanned 12 weeks, with each weekly session lasting for two hours. The program is structured around three thematic domains of the past, present, and future. In each thematic domain consisting of four weeks, participants were tasked with creating an artwork related to the theme and incorporating the learned art techniques. The structure of each thematic domain follows the same structure: the first week involved a 45-minute docent-led gallery tour on three selected pieces of artworks, followed by a 75-minute artist-led brainstorming session where participants were introduced to the techniques and discuss ideas on the artwork to be created. The subsequent three sessions involved further guidance from the artist and a scaffolded delivery of art techniques for participants to incorporate their learning to their artwork. At the end of each domain, there was a showcase where participants present their artwork.
Study: NCT05151900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Group for Caregivers
Description: Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children.
Study: NCT04810988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: The Unified Protocol is an empirically supported, transdiagnostic treatment for emotion disorders based on principles of cognitive behavioral therapy. Treatment focuses on increasing awareness of maladaptive thoughts and behaviors and decreasing avoidance of emotions and physiological sensations. Module 1 is focused on increasing motivation, readiness and self-efficacy for change. Module 2 focuses on increasing understanding and awareness of emotions. Module 3 is focused on further expanding awareness of emotions. Module 4 focuses on the role of thoughts in emotional disorders. Module 5 is focused on the role of behaviors in emotional disorders. Module 6 focuses on the role of physical sensations in emotional disorders. Module 7 focuses on exposure to interoceptive and situational triggers for emotions. Module 8 is focused on maintenance of treatment progress and relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol
Description: The Unified Protocol is an empirically supported, transdiagnostic treatment for emotion disorders based on principles of cognitive behavioral therapy. Treatment focuses on increasing awareness of maladaptive thoughts and behaviors and decreasing avoidance of emotions and physiological sensations. Module 1 is focused on increasing motivation, readiness and self-efficacy for change. Module 2 focuses on increasing understanding and awareness of emotions. Module 3 is focused on further expanding awareness of emotions. Module 4 focuses on the role of thoughts in emotional disorders. Module 5 is focused on the role of behaviors in emotional disorders. Module 6 focuses on the role of physical sensations in emotional disorders. Module 7 focuses on exposure to interoceptive and situational triggers for emotions. Module 8 is focused on maintenance of treatment progress and relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist Support
Description: 4 video calls with study therapists
Study: NCT05526131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionare
Description: Assessing the presence or the absence of depression:~By structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionare
Description: Assessing the presence or the absence of depression:~By structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders.
Study: NCT05833100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CareSens PRO GK Blood Glucose/b-Ketone Monitoring system
Description: All BG results were compared to YSI 2300 reference method results obtained from subjects' capillary blood.~All Ketone results were compared to Randox Imola D-3-Hydroxybutyrate analyzer.
Study: NCT05412251

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: health promotion program
Description: Multi-domain intervention 120 minutes cognitive training, 120 \~180 minutes physical exercise per weeks, and 60 minutes diet nutrition education per month
Study: NCT04958200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mhealth-pc for alcohol and pain
Description: Smartphone-based intervention that includes in-person initial session and 8 video lessons, daily activities, and weekly check-ins.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: psychoeducation on pain and alcohol use and treatment resource information
Study: NCT05898841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day
Description: DTG/RPV will be administered in combination as 50/25 mg/day tablets or separately as DTG 50 mg/d tablets together with RPV 25 mg/d tablets. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART (Highly Active Antiretroviral Therapy) components are respected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day
Description: TDF 245 mg/d or TAF 25mg/d together with FTC 200 mg/d and RPV 25 mg/d. They may be administered as single tablets or in combination forms where one tablet contains TDF/TAF and FTC and another RPV tablet. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART components are respected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.
Description: Patients who are randomised to this treatment arm will continue with the HAART they were receiving prior to signing the informed consent. As in arms 1 and 2, a change in the form of HAART administration (from a combined to a separate form and vice versa) will be allowed as long as the HAART components are respected.
Study: NCT04827472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 100ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 100ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 100ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 100ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1521
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1521
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1521
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1521
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1521
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 Tablet
Description: Single dose, Tablet
Study: NCT05834062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia and lifestyle management therapy
Description: Qsymia will be used at 3.7g mg/23 mg for 12 weeks and then increased to 7.5 mg/46 mg for the remainder of the study. Participants will be offered lifestyle management therapy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and lifestyle management therapy
Description: Placebo will be used in lieu of Qsymia to maintain the blind. Participants will be offered lifestyle management therapy.
Study: NCT05485922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device - intermittent catheter with a micro-hole zone
Description: The investigational device was a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator device -VaPro intermittent catheter
Description: The comparator device is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
Study: NCT05722262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: K-877-ER and CSG452 combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: K-877-ER and CSG452 combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: K-877-ER and CSG452 combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: K-877-ER and CSG452 combination tablet
Study: NCT05479032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: 2x100 mg Amantadine for 3-5 days (dosage can be doubled in case of missing response to treatment after 48 hours)
Study: NCT06045793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-1300 (Injection)
Description: Patients will receive a single IV injection of TNX-1300.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Injection)
Description: Patients will receive a single IV injection of placebo with usual care (UC).
Study: NCT05543707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 (Pomotrelvir)
Description: 2 × 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 × placebo to match PBI-0451(Pomotrelvir) tablets administered orally BID with food for 5 days (10 total doses)
Study: NCT05336630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forceps
Description: The forceps clears the redundant tissue to enable access to the papilla, as well as stabilizes the ampullary position to permit an easier cannulation. The forceps is an FDA approved instrument and does not put the patient at any higher risk for any adverse event. Please note that for the explicit purpose of the study the forceps will be used to grab tissue and not take biopsies. The forceps may still be used to take biopsies if the physician believes it is indicated.
Study: NCT05020535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW189
Description: MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
Study: NCT06145438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: Drug is administered orally at the same time every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo Medroxyprogesterone acetate
Description: Drug is injected intramuscularly on the buttock

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide (as Leuprolide Acetate)
Description: Drug is injected intramuscularly on the buttock

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)
Description: Drug is administered orally at the same time every day
Study: NCT05540613

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education
Description: A 26 weeks brain health and general health education program with two 1.5-hour sessions weekly.
Study: NCT05722262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: K-877-ER and CSG452 combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: K-877-ER and CSG452 combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER
Description: K-877-ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER
Description: K-877-ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER
Description: K-877-ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER
Description: K-877-ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER
Description: K-877-ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER
Description: K-877-ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSG452
Description: CSG452 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSG452
Description: CSG452 tablet
Study: NCT05540613

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise
Description: A 26 weeks Conventional Exercise training with two 1.5-hour sessions weekly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: A 26 weeks Tai Chi training with two 1.5-hour sessions weekly.
Study: NCT06515821

Intervention type: DIAGNOSTIC_TEST
Intervention: ONCOSCREEN
Description: Subjects samples will be tested with diagnostic tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: ONCOSCREEN
Description: Subjects samples will be tested with diagnostic tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: ONCOSCREEN
Description: Subjects samples will be tested with diagnostic tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: ONCOSCREEN
Description: Subjects samples will be tested with diagnostic tests.
Study: NCT06295354

Intervention type: OTHER
Intervention: No intervention, we just study 'aging'
Description: No intervention, we just study 'aging'

Intervention type: OTHER
Intervention: No intervention, we just study 'aging'
Description: No intervention, we just study 'aging'

Intervention type: OTHER
Intervention: No intervention, we just study 'aging'
Description: No intervention, we just study 'aging'

Intervention type: OTHER
Intervention: No intervention, we just study 'aging'
Description: No intervention, we just study 'aging'
Study: NCT05447650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-Lumen(TM) AMD
Description: Transpalpebral microcrurrent stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: i-Lumen(TM) AMD Sham
Description: Transpalpebral sham stimulation
Study: NCT05692596

Intervention type: OTHER
Intervention: Data collection
Description: Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.
Study: NCT04617340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted clinical pharmacy intervention
Description: 1. Assessing patient and caregiver preferences~2. Medication reconciliation on admission~3. Performing a comprehensive medication review before discharge~4. Promoting safe transition~4.a. Compiling a patient friendly medication list~4.b.Optimizing communication with healthcare providers in primary care:~4.b.i.Providing a copy of the medication list for the community pharmacist~4.b.ii. Contacting the general practitioner by phone~4.b.iii. Contacting, if applicable the home care nurse or the nurse from the nursing home by phone.~5.A motivation interview will take place before discharge with patients and caregivers~6.Post-discharge follow-up: 6.a.Follow-up call to discuss potential drug therapy issues, therapy adherence and to resolve any pending issues 6.b.A telepharmacology service will be provided to primary healthcare professionals as a means to consult the ward-based clinical pharmacists and/or research team after discharge.
Study: NCT06104813

Intervention type: OTHER
Intervention: Interviews
Description: Interview with volunteer, to ask them a series of open questions about sexual health in the deaf male population.
Study: NCT05722262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSG452
Description: CSG452 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSG452
Description: CSG452 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSG452
Description: CSG452 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSG452
Description: CSG452 tablet
Study: NCT06293274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discharge training
Description: What is motherhood blues? Why does it occur? What are its symptoms? How to deal with it? What is postpartum depression? What causes postpartum depression? Information is provided on this topic.
Study: NCT05751798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE-279 100mg
Description: Human IgG4 mAb against PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE-279 300mg
Description: Human IgG4 mAb against PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE-279 500mg
Description: Human IgG4 mAb against PD-1
Study: NCT05468255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: removal of exercise
Description: Subjects will stop doing their normal exercise routines for 3 or 5 days and then subjects will resume doing their normal exercise routines for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: removal of exercise
Description: Subjects will stop doing their normal exercise routines for 3 or 5 days and then subjects will resume doing their normal exercise routines for 3 days.
Study: NCT05975814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implant
Description: dental implants are placed as usual and require a healing abutment. Abutments can be straight or concave, both are equally available on the market.
Study: NCT05750498

Intervention type: OTHER
Intervention: No interventions
Description: There are no interventions
Study: NCT05061420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical Form: Concentration for solution for infusion Route of Administration: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical Form: Concentration for solution for infusion Route of Administration: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444245 (Thor-707)
Description: Pharmaceutical Form: Concentrate for solution for infusion Route of Administration: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444245 (Thor-707)
Description: Pharmaceutical Form: Concentrate for solution for infusion Route of Administration: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444245 (Thor-707)
Description: Pharmaceutical Form: Concentrate for solution for infusion Route of Administration: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous Infusion
Study: NCT06649331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009
Description: A HER3-directed ADC, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102
Description: A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.
Study: NCT04854824

Intervention type: DRUG
Intervention: Recommended treatment schedule
Description: Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy

Intervention type: DRUG
Intervention: Control treatment schedule
Description: Treatment regimens different from the recommended one according to family physician personal practice